Cyclo Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 20.06 million compared to USD 15.45 million a year ago. Basic loss per share from continuing operations was USD 1.23 compared to USD 1.83 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 USD | +2.19% | -4.76% | -11.95% |
01/05 | HC Wainwright Starts Cyclo Therapeutics With Buy Rating, $3 Price Target | MT |
18/03 | Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-11.95% | 40.2M | |
+32.09% | 693B | |
+29.39% | 584B | |
-1.34% | 372B | |
+20.34% | 332B | |
+7.39% | 294B | |
+14.25% | 239B | |
-3.03% | 211B | |
+10.02% | 210B | |
+8.49% | 168B |
- Stock Market
- Equities
- CYTH Stock
- News Cyclo Therapeutics, Inc.
- Cyclo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023